Sonnet BioTherapeutics (SONN) Stock Price, News & Analysis

Company Overview

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage biotechnology company dedicated to developing innovative cytokine-based therapeutics for oncology and autoimmune disorders. The company’s platform centers on engineering human cytokines, notably interleukin-2 and related molecules, fused to carrier proteins such as human serum albumin. This design aims to extend circulating half-life, enhance tumor localization, and minimize systemic toxicity compared with traditional cytokine therapies.

Sonnet’s lead pipeline candidates are in early-phase clinical trials for the treatment of solid tumors, where the company seeks to demonstrate improved efficacy and safety. In parallel, Sonnet is advancing preclinical immunocytokine programs targeting specific aspects of the tumor microenvironment to further leverage its fusion protein technology across multiple cancer indications.

Headquartered in San Diego, California, Sonnet BioTherapeutics conducts research and development operations in the United States. The management team comprises seasoned industry professionals with expertise in immuno-oncology, biologics development, and clinical strategy, positioning the company to progress its pipeline toward later-stage trials and potential partnerships.

Key Stats

• Today's Range: $4.90 to $5.55
• 50-Day Range: $2.65 to $7.58
• 52-Week Range: $1.08 to $19.30
• Volume: 571,660 shs
• Average Volume: 1.56 million shs
• Market Capitalization: $34.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.00
• Consensus Rating: Hold

Sonnet BioTherapeutics Stock Analysis - MarketRank™

Sonnet BioTherapeutics scored higher than 35% of companies evaluated by MarketBeat, and ranked 736th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Sonnet BioTherapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Sonnet BioTherapeutics has a consensus price target of $20.00, representing about 295.6% upside from its current price of $5.06.

Amount of Analyst Coverage

Sonnet BioTherapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

34.15% of the float of Sonnet BioTherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Sonnet BioTherapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sonnet BioTherapeutics has recently increased by 19.79%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sonnet BioTherapeutics does not currently pay a dividend.

Dividend Growth

Sonnet BioTherapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

34.15% of the float of Sonnet BioTherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Sonnet BioTherapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sonnet BioTherapeutics has recently increased by 19.79%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

13 people have searched for SONN on MarketBeat in the last 30 days. This is an increase of 333% compared to the previous 30 days.

MarketBeat Follows

2 people have added Sonnet BioTherapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sonnet BioTherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.48% of the stock of Sonnet BioTherapeutics is held by insiders.

Percentage Held by Institutions

Only 9.45% of the stock of Sonnet BioTherapeutics is held by institutions.

SONN Stock Analysis - Frequently Asked Questions

How have SONN shares performed this year?

Sonnet BioTherapeutics' stock was trading at $1.46 at the beginning of 2025. Since then, SONN stock has increased by 246.2% and is now trading at $5.0550.

How were Sonnet BioTherapeutics' earnings last quarter?

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) issued its quarterly earnings results on Wednesday, August, 13th. The company reported ($0.95) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by $0.46.

When did Sonnet BioTherapeutics' stock split?

Sonnet BioTherapeutics shares reverse split on Sunday, September 29th 2024.The 1-8 reverse split was announced on Sunday, September 29th 2024. The number of shares owned by shareholders was adjusted after the market closes on Sunday, September 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

How do I buy shares of Sonnet BioTherapeutics?

Shares of SONN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sonnet BioTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sonnet BioTherapeutics investors own include Plug Power (PLUG), SNDL (SNDL), NIO (NIO), Zomedica (ZOM), VYNE Therapeutics (VYNE), Avino Silver & Gold Mines (ASM) and Dare Bioscience (DARE).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 10/07/2025
• Next Earnings (Estimated): 12/16/2025
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SONN
• CIK: 1106838
• Web: www.chanticleerholdings.com
• Phone: 609-375-2227
• Fax: 704-366-2463
• Employees: 10
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Sonnet BioTherapeutics: $20.00
• High Price Target: $20.00
• Low Price Target: $20.00
• Potential Upside/Downside: +278.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.44 million
• Net Margins: N/A
• Pretax Margin: -1,339.60%
• Return on Equity: -4,646.10%
• Return on Assets: -342.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.26
• Quick Ratio: 0.26

Sales & Book Value

• Annual Sales: $1 million
• Price / Sales: 36.08
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.71) per share
• Price / Book: -7.44

Miscellaneous

• Outstanding Shares: 6,827,000
• Free Float: 6,248,000
• Market Cap: $36.08 million
• Optionable: Not Optionable
• Beta: 1.34